<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diatrizoate meglumine and diatrizoate sodium (Gastrografin): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diatrizoate meglumine and diatrizoate sodium (Gastrografin): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Diatrizoate meglumine and diatrizoate sodium (Gastrografin): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11626" href="/d/html/11626.html" rel="external">see "Diatrizoate meglumine and diatrizoate sodium (Gastrografin): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F158959"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Gastrografin;</li>
<li>MD-Gastroview [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52911969"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Gastrografin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F158961"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Iodinated Contrast Media;</li>
<li>
                        Radiological/Contrast Media (Ionic, High Osmolality)</li></ul></div>
<div class="block doa drugH1Div" id="F1751178"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="468f1f92-0047-474e-b3c2-16cddb63065c">Radiographic exam of GI tract segments</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Radiographic exam of GI tract segments:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 30 to 90 mL; decrease dose in debilitated or dehydrated patients.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Rectal enema/enterostomy instillation:</b> Dilute 240 mL in 1,000 mL tap water.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="33458163-463e-4478-b8da-ec859b4ae294">Tomography</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tomography:</b>
<b>Oral:</b> Dilute 25 to 77 mL in 1000 mL tap water, then administer 240 mL of this solution 15 to 30 minutes prior to imaging.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990556"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987897"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F1751179"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Radiographic exam of GI tract segments:</b>
<b>Oral:</b> 30 to 90 mL; If patient has cachexia, a 1:1 dilution of the oral solution using a recommended liquid is recommended. Decrease dose in debilitated or dehydrated patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Other indications:</b> Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F1751177"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e06dbb96-838e-406b-a1aa-1975ba2825e1">Angiocardiography</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Angiocardiography:</b> IV (injected into larger peripheral vein or by direct catheterization of the heart):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;5 years: 10 to 20 mL. <b>Note:</b> The risk of using this dose in children weighing &lt;7 kg is increased especially if infants have pre-existing right heart strain, right heart failure, or decreased or obliterated pulmonary vascular beds.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 5 to 10 years: 20 to 30 mL; up to 100 mL have been administered.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c31dc571-9920-4b8b-9e45-38c447b8ccc7">Aortography</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aortography:</b> IV or intra-arterial: Adolescents &gt;16 years: Refer to adult dosing.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d4d8e6aa-5bd8-4cca-b2ee-134bce4202bc">Excretory urography</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Excretory urography:</b> IV: Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;6 months: 4 mL</p>
<p style="text-indent:-2em;margin-left:4em;">6 to 12 months: 6 mL</p>
<p style="text-indent:-2em;margin-left:4em;">1 to 2 years: 8 mL</p>
<p style="text-indent:-2em;margin-left:4em;">2 to 5 years: 10 mL</p>
<p style="text-indent:-2em;margin-left:4em;">5 to 7 years: 12 mL</p>
<p style="text-indent:-2em;margin-left:4em;">8 to 10 years: 14 mL</p>
<p style="text-indent:-2em;margin-left:4em;">11 to 15 years: 16 mL</p>
<p style="text-indent:-2em;margin-left:4em;">≥16 years: Refer to adult dosing</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Ensure low residue diet the day prior to procedure with a laxative given the evening prior to the procedure unless contraindicated. Do not fluid restrict infants and young children prior to procedure.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5e5c938f-009d-401a-808a-5e2ecfa0afff">Peripheral arteriography</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral arteriography:</b> Intra-arterial (femoral or subclavian artery): Children and Adolescents: Adjust adult dose proportionally based on body weight. Consult product labeling for additional procedure specific warnings/precautions.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="468f1f92-0047-474e-b3c2-16cddb63065c">Radiographic exam of GI tract segments</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Radiographic exam of GI tract segments:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children &lt;5 years: 30 mL; may dilute 1:1 in a recommended liquid (if patient &lt;10 kg or debilitated, should dilute 1:3 in water).</p>
<p style="text-indent:-2em;margin-left:6em;">Children 5 to 10 years: 60 mL; may dilute 1:1 in a recommended liquid (if patient &lt;10 kg or debilitated, should dilute 1:3 in water).</p>
<p style="text-indent:-2em;margin-left:6em;">Children &gt;10 years and Adolescents: Dosage varies.</p>
<p style="text-indent:-2em;margin-left:4em;">Rectal enema/enterostomy instillation:</p>
<p style="text-indent:-2em;margin-left:6em;">Children &lt;5 years: Dosage varies. Dilute 1:5 in tap water.</p>
<p style="text-indent:-2em;margin-left:6em;">Children &gt;5 years: Dilute 90 mL in 500 mL tap water.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51109209"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling. Use caution in severe impairment and in setting of combined renal and hepatic disease.</p></div>
<div class="block dohp drugH1Div" id="F51109210"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling. Use caution in patients with combined hepatic and renal disease.</p></div>
<div class="block adr drugH1Div" id="F1751166"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reactions listed are based on reports for other agents in this same pharmacologic class and may not be specifically reported for diatrizoate meglumine and diatrizoate sodium. Also see diatrizoate meglumine.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Tachyarrhythmia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperthyroidism</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (acute), hypoxia</p></div>
<div class="block coi drugH1Div" id="F158954"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to diatrizoate or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F1751163"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aspiration: Aspiration may occur following oral administration; serious complications may result due to the formation of a copious osmotic effusion. Avoid use in patients with esophagotracheal fistula; ensure proper positioning of the tube in the stomach prior to administration via nasogastric tube.</p>
<p style="text-indent:-2em;margin-left:4em;">• Contrast media reactions: Adverse reactions (including delayed reactions) to iodine-containing contrast media have occurred. Most cases are minor; however, serious and life-threatening reactions may occur without warning and often resemble allergic-type reactions. Patients with a history of bronchial asthma, allergy (including food allergy), family history of allergy, or prior allergy or hypersensitivity to contrast agents are at a higher risk for allergic reaction. Obtain allergy and hypersensitivity history prior to administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dehydration: Use of hypertonic oral/rectal contrast solutions may cause hypovolemia and hypotension due to fluid loss from the intestines. Specific dilution guidelines are provided for administering solutions to young children, children &lt;10 kg, older adults, or dehydrated and/or debilitated persons. Correct electrolyte imbalances prior to administration of hypertonic contrast solutions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperacidity: Conditions that promote GI hyperacidity (eg, fasting, emotional upset, stress) may lead to the precipitation of orally administered water-soluble contrast agents; potential for false interpretation of precipitate as a GI anatomical abnormality or injury should be kept in mind.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperthyroidism: Cases of hyperthyroidism have been reported with the use of oral contrast media. Use with caution in patients who are hyperthyroid or euthyroid with a goiter.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use may worsen myasthenia gravis (MG); use with caution and monitor for worsening MG (AAN [Narayanaswami 2021]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Debilitated patients: Use oral/rectal hypertonic contrast agents with caution in debilitated patients due to the potential for fluid loss from the intestine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Use with caution in older adult patients. Hypovolemia, hypotension, and shock may occur in older adult patients with cachexia following oral/rectal administration of the hypertonic contrast agent solution if dilution instructions are not followed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Use with caution in children. Injury to the colonic mucosa may occur if oral/rectal dilution instructions are not followed; risk may be increased with underlying diseases that affect intestinal viability. Hypovolemia, hypotension, and shock may occur in young, debilitated children following oral/rectal administration of the hypertonic contrast agent solution if dilution instructions are not followed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Rectal administration: Undiluted solutions may cause mucosal irritation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Trained personnel: Clinicians using radiopaque contrast agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use during and after administration (delayed reactions have occurred).</p></div>
<div class="block foc drugH1Div" id="F158951"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gastrografin: Diatrizoate meglumine 660 mg and diatrizoate sodium 100 mg per 1 mL (30 mL, 120 mL) [contains disodium edta, polysorbate 80, saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">MD-Gastroview: Diatrizoate meglumine 660 mg and diatrizoate sodium 100 mg per 1 mL (30 mL [DSC]) [contains disodium edta, saccharin sodium; lemon-vanilla flavor]</p></div>
<div class="block geq drugH1Div" id="F158948"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323106"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Gastrografin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">66-10% (per mL): $0.97</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F53666598"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Combination: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gastrografin: 66-10 % (30 mL, 120 mL) [contains edetate (edta) sodium (tetrasodium), polysorbate 80, saccharin sodium]</p></div>
<div class="block adm drugH1Div" id="F1751180"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> May be administered diluted. May be diluted 1:1 with water, carbonated beverage, milk, or mineral oil for older adults with cachexia. Maintain an open IV fluid line in pediatric or severely debilitated patients in case hypotension or shock occurs and rehydration is required.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rectal:</b> Administer diluted prior to enema or enterostomy instillation.</p></div>
<div class="block admp drugH1Div" id="F52612530"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: MD-76 R: IV, Intra-arterial: Administer at body temperature; may need to be warmed before use. Slow or stop the injection if a minor reaction occurs during administration; discontinue if a major reaction occurs. Patient should omit the meal that precedes the examination. Appropriate premedication (eg, barbiturate, tranquilizer, or an analgesic) may be administered prior to the examination. Patients with a strong allergic history may receive an antihistamine within 30 minutes of administration of the contrast agent and corticosteroids prior to and for 24 hours after the contrast agent. Procedure specific administration considerations should also be reviewed; see product labeling for details.</p>
<p style="text-indent:-2em;margin-left:4em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect; remove needle/cannula; elevate extremity. Aspiration of extravasated contrast media is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.1'])">Ref</a></span>). Information conflicts regarding the use of hyaluronidase; the American College of Radiology (ACR) Manual on Contrast Media does not recommend hyaluronidase in the management of contrast media extravasation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.1'])">Ref</a></span>); other sources suggest its utility in extravasation management (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12386778','lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12386778','lexi-content-ref-24420913'])">Ref</a></span>) (see Management of Drug Extravasations for more details).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: May be diluted prior to administration. May administer in a bottle to infants. Maintain an open IV fluid line in case hypotension or shock occurs and rehydration is required.</p>
<p style="text-indent:-2em;margin-left:4em;">Nasogastric tube: If ng administration is necessary, tube position must be verified prior to administration</p>
<p style="text-indent:-2em;margin-left:2em;">Rectal: Dilute prior to enema or enterostomy instillation.</p></div>
<div class="block use drugH1Div" id="F158952"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Imaging:</b> Oral/rectal: Radiographic examination of GI tract; adjunct to contrast enhancement in computed tomography of the torso (in conjunction with an IV radiopaque contrast agent).</p></div>
<div class="block cyt drugH1Div" id="F13299176"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6219796"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aldesleukin: May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the nephrotoxic effect of Iodinated Contrast Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Iodide I131: Iodinated Contrast Agents may diminish the therapeutic effect of Sodium Iodide I131.  Management: Discontinue iodinated contrast agents before sodium iodide I-131 administration, and avoid concurrent use. Stop water soluble agents 2 months before, and stop lipophilic agents 6 months before, sodium iodide I-131 administration.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F158956"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Following IV administration, diatrizoate salts cross the placenta and may enter fetal circulation.</p>
<p style="text-indent:0em;margin-top:2em;">Due to theoretical concerns that exposure to free iodide may adversely affect the fetus, use should be avoided unless absolutely required to obtain diagnostic information that will influence the care of the mother or fetus during pregnancy (ACOG 723 2017; ACR 2021).</p></div>
<div class="block brc drugH1Div" id="F158957"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Iodine can be detected in breast milk following diatrizoate meglumine injection (Weyrauch 1977).</p>
<p style="text-indent:-2em;margin-left:2em;">Because of the low expected excretion of iodinated contrast agents into breast milk and the low absorption from an infant's GI tract, breastfeeding may be continued without interruption (ACOG 723 2017; ACR 2021). Theoretically, the taste of milk could be altered if it contains contrast media. Patients who prefer to temporarily withhold breastfeeding may express and discard milk from both breasts during a period of 12 to 24 hours after the administration of contrast media. They can pump and store milk prior to the procedure then bottle feed using the stored milk during this time (ACR 2021).</p></div>
<div class="block mop drugH1Div" id="F15670086"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Hydration, serum osmolarity, and electrolyte status in debilitated patients and in patients with electrolyte imbalances. Procedure specific monitoring considerations should also be reviewed; see product labeling for details.</p></div>
<div class="block pha drugH1Div" id="F26998844"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Radiopaque contrast agent; opacifies vessels or tissues in the path of the flow of the contrast medium, permitting radiographic visualization of the internal structures of the body.</p></div>
<div class="block phk drugH1Div" id="F15669974"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Sparingly absorbed following oral administration.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038598"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Gastrografin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Gastrografin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-28937575">
<a name="28937575"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee opinion no. 723: guidelines for diagnostic imaging during pregnancy and lactation. <i>Obstet Gynecol</i>. 2017;130(4):e210-e216.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diatrizoate-meglumine-and-diatrizoate-sodium-gastrografin-drug-information/abstract-text/28937575/pubmed" id="28937575" target="_blank">28937575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACR.1">
<a name="ACR.1"></a>American College of Radiology (ACR) Committee on Drugs and Contrast Media. ACR manual on contrast media. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf. Published 2021. Accessed March 23, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12386778">
<a name="12386778"></a>Bellin MF, Jakobsen JA, Tomassin I, et al; Contrast Media Safety Committee of the European Society of Urogenital Radiology. Contrast medium extravasation injury: guidelines for prevention and management. <i>Eur Radiol</i>. 2002;12(11):2807-2812. doi:10.1007/s00330-002-1630-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diatrizoate-meglumine-and-diatrizoate-sodium-gastrografin-drug-information/abstract-text/12386778/pubmed" id="12386778" target="_blank">12386778</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Gastrografin (diatrizoate meglumine and diatrizoate sodium) [prescribing information]. Monroe Township, NJ: Bracco Diagnostics Inc; August 2019.</div>
</li>
<li>
<div class="reference">
                  Gastrografin (diatrizoate meglumine and diatrizoate sodium) [product monograph]. Montreal, Quebec, Canada: Bracco Imagining Canada; April 2022.</div>
</li>
<li>
<div class="reference">
                  MD-Gastroview (diatrizoate meglumine and diatrizoate sodium) [prescribing information]. Raleigh, NC: Liebel-Flarsheim Company; August 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144515">
<a name="33144515"></a>Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. <i>Neurology</i>. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diatrizoate-meglumine-and-diatrizoate-sodium-gastrografin-drug-information/abstract-text/33144515/pubmed" id="33144515" target="_blank">33144515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632. doi:10.1002/phar.1396<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diatrizoate-meglumine-and-diatrizoate-sodium-gastrografin-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-143435">
<a name="143435"></a>Weyrauch U, Volkhardt V, Speck U. Transfer of amidotrizoate in maternal milk following phlebography in a patient 10 days post partum. <i>Rofo</i>. 1977;127(3):275-276.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diatrizoate-meglumine-and-diatrizoate-sodium-gastrografin-drug-information/abstract-text/143435/pubmed" id="143435" target="_blank">143435</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8542 Version 166.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
